Chad Borges

Prof. Chad Borges

Arizona State University, School of Molecular Sciences
+1

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2020 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
JLJesús Aguilar Diaz De Leon
Jesús Aguilar Diaz De Leon
CBChad Borges
Chad Borges
Despite its limited analytical specificity and ruggedness, the thiobarbituric acid reactive substances (TBARS) assay has been widely used as a generic metric of lipid peroxidation in biological fluids. It is often considered a good indicator of the levels of oxidative stress within a biological sample, provided that the sample has been properly handled and stored. The assay involves the reaction of lipid peroxidation products, primarily malondialdehyde (MDA), with thiobarbituric acid (TBA), which leads to the formation of MDA-TBA2 adducts called TBARS. TBARS yields a red-pink color that can be measured spectrophotometrically at 532 nm. The TBARS assay is performed under acidic conditions (pH = 4) and at 95 °C. Pure MDA is unstable, but these conditions allow the release of MDA from MDA bis(dimethyl acetal), which is used as the analytical standard in this method. The TBARS assay is a straightforward method that can be completed in about 2 h. Preparation of assay reagents are described in detail here. Budget-conscious researchers can use these reagents for multiple experiments at a low cost rather than buying an expensive TBARS assay kit that only permits construction of a single standard curve (and thus can only be used for one experiment). The applicability of this TBARS assay is shown in human serum, low density lipoproteins, and cell lysates. The assay is consistent and reproducible, and limits of detection of 1.1 μM can be reached. Recommendations for the use and interpretation of the spectrophotometric TBARS assay are provided.

27 July 2010 in Biochemistry
Verified
Journal Article
Closed access
DRDouglas S. Rehder
Douglas S. Rehder
CBChad Borges
Chad Borges

8 August 2008 in Journal of Proteome Research
Verified
Journal Article
Closed access
CBChad Borges
Chad Borges
JJJason W. Jarvis
Jason W. Jarvis
POPaul E. Oran
Paul E. Oran
RNRandall W. Nelson
Randall W. Nelson

24 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
POPaul E. Oran
Paul E. Oran
OTOlgica Trenchevska
Olgica Trenchevska
DNDobrin Nedelkov
Dobrin Nedelkov
CBChad Borges
Chad Borges
MSMatthew R. Schaab
Matthew R. Schaab
RNRandall W. Nelson
Randall W. Nelson
Insulin-like growth factor 1 (IGF1) is an important biomarker for the management of growth hormone disorders. Recently there has been rising interest in deploying mass spectrometric (MS) methods of detection for measuring IGF1. However, widespread clinical adoption of any MS-based IGF1 assay will require increased throughput and speed to justify the costs of analyses, and robust industrial platforms that are reproducible across laboratories. Presented here is an MS-based quantitative IGF1 assay with performance rating of >1,000 samples/day, and a capability of quantifying IGF1 point mutations and posttranslational modifications. The throughput of the IGF1 mass spectrometric immunoassay (MSIA) benefited from a simplified sample preparation step, IGF1 immunocapture in a tip format, and high-throughput MALDI-TOF MS analysis. The Limit of Detection and Limit of Quantification of the resulting assay were 1.5 μg/L and 5 μg/L, respectively, with intra- and inter-assay precision CVs of less than 10%, and good linearity and recovery characteristics. The IGF1 MSIA was benchmarked against commercially available IGF1 ELISA via Bland-Altman method comparison test, resulting in a slight positive bias of 16%. The IGF1 MSIA was employed in an optimized parallel workflow utilizing two pipetting robots and MALDI-TOF-MS instruments synced into one-hour phases of sample preparation, extraction and MSIA pipette tip elution, MS data collection, and data processing. Using this workflow, high-throughput IGF1 quantification of 1,054 human samples was achieved in approximately 9 hours. This rate of assaying is a significant improvement over existing MS-based IGF1 assays, and is on par with that of the enzyme-based immunoassays. Furthermore, a mutation was detected in ∼1% of the samples (SNP: rs17884626, creating an A→T substitution at position 67 of the IGF1), demonstrating the capability of IGF1 MSIA to detect point mutations and posttranslational modifications.

23 September 2009 in Protein Science
Verified
Journal Article
Open access
PDF file
DRDouglas S. Rehder
Douglas S. Rehder
RNRandall W. Nelson
Randall W. Nelson
CBChad Borges
Chad Borges
On the basis of the results of activity studies, previous reports have suggested that vitamin D binding protein (DBP) is significantly or even completely deglycosylated in cancer patients, eliminating the molecular precursor of the immunologically important Gc macrophage activating factor (GcMAF), a glycosidase‐derived product of DBP. The purpose of this investigation was to directly determine the relative degree of O‐linked trisaccharide glycosylation of serum‐derived DBP in human breast, colorectal, pancreatic, and prostate cancer patients. Results obtained by electrospray ionization‐based mass spectrometric immunoassay showed that there was no significant depletion of DBP trisaccharide glycosylation in the 56 cancer patients examined relative to healthy controls. These results suggest that alternative hypotheses regarding the molecular and/or structural origins of GcMAF must be considered to explain the relative inability of cancer patient serum to activate macrophages.

21 May 2013 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
PDF file
HYHussein Yassine
Hussein Yassine
CBChad Borges
Chad Borges
MSMatthew R. Schaab
Matthew R. Schaab
DBDean Billheimer
Dean Billheimer
CSCraig Stump
Craig Stump
RNRandall Nelson
Randall Nelson